Apigenin

Clinical Summary

Apigenin is the predominant flavone in parsley, celery, and chamomile, and the signature bioactive in Matricaria recutita. It rose to supplement-industry prominence via two narratives: (1) GABA-A benzodiazepine-site modulation underlying chamomile's mild anxiolytic/sedative effects, and (2) CD38 inhibition → NAD+ preservation → SIRT1/SIRT3 activation as an "anti-aging" mechanism. The first narrative has modest human evidence in generalised anxiety disorder (Amsterdam 2009 and Mao 2016 — both UPenn, placebo-controlled, single-center, modest effect sizes). The second narrative is mechanistically coherent but entirely preclinical in humans — there is zero human data showing oral apigenin raises NAD+, inhibits CD38 in vivo, or produces any longevity-relevant biomarker change.

A 2025 landmark paper (PMID 40265973, Buck Institute + Shanghai collaboration) reclassified apigenin as a senomorphic (SASP-suppressing via PRDX6/HSPA8/ATM-p38MAPK axis) rather than a classic senolytic — an important mechanistic distinction from fisetin or dasatinib+quercetin. Community marketing that calls apigenin "senolytic" is imprecise.

Native oral bioavailability is poor (~5% in rodents; human plasma glucuronides after parsley/chamomile peak at Tmax ~7h and are mostly conjugated metabolites). Most marketed apigenin at 50 mg/d likely delivers sub-pharmacologic free-aglycone exposure. SNEDDS, co-amorphous, liposomal, and phytosomal formulations are active 2024-2025 research targets.

Who benefits most: (a) people seeking a mild, low-side-effect anxiolytic adjunct and willing to accept modest effect size; (b) biohackers running longevity stacks who understand they are betting on preclinical data; (c) postmenopausal women with vasomotor symptoms who prefer herbal extracts over HRT. Who should approach cautiously: hormone-sensitive cancer patients (phytoestrogen — signal could cut either way), people on narrow-therapeutic-index CYP1A2/CYP3A4 substrates at high apigenin doses, and Asteraceae-allergic individuals (chamomile cross-reactivity with ragweed).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = evidence kind (legend below). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. Hard rule: Star rating cannot exceed the causal-taxonomy ceiling for its Type. AHE (animal→human) and ME (mechanistic extrapolation) cap at 2/5 regardless of how many rodent studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (/9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none. Safety flags: -- No signals (or no FAERS data, common for supplements) | MON Monitor (manageable AEs) | WARN FAERS or trial safety signal | AVOID Contraindicated for this use.

Star legend: 5/5=multiple large RCTs + meta-analyses | 4/5=several human RCTs | 3/5=some human pilot | 2/5=animal only or very limited human | 1/5=none / debunked.

Prescribing

Dosing Table

Formulation Table

Safety

Interactions Table

Contraindications

• Pregnancy and lactation: No safety data. Phytoestrogenic classification + historical use of chamomile as emmenagogue warrant avoidance.
• Asteraceae / ragweed allergy: Chamomile formulations cross-react (documented contact dermatitis, rare anaphylaxis). Isolated apigenin has no direct allergen data but patients with known chamomile allergy should avoid chamomile-derived products.
• Active hormone-sensitive cancer (ER+ breast, endometrial): No RCT evidence either direction; ambiguous receptor behavior (estrogenic OR antiestrogenic depending on context and dose). Default caution.
• Scheduled surgery within 2 weeks: Discontinue due to theoretical coagulation interaction (chamomile coumarins) and CYP interactions with anesthetics.
• Children <12 years: No dosing or safety data for apigenin isolate. Chamomile tea/extract has traditional pediatric use but isolated apigenin does not.

Adverse Effects (ranked by reported frequency)

1. Allergic / contact reactions (chamomile-derived, Asteraceae cross-reactivity): mouth sores, skin spots, itching — 2/40 dropouts in the menopause RCT (PMID 39836709).
2. GI upset / nausea at >150 mg or on empty stomach (community reports).
3. Paradoxical anxiety / sleep disruption (recurring but minority forum reports across Reddit and Longecity).
4. Morning grogginess if dosed too close to waking; reduced by splitting or co-dosing magnesium.
5. Vivid / lucid dreams — reported as desirable by lucid-dream community, disruptive by some insomniacs.
6. Theoretical but not observed in practice at 50–300 mg/d: gynecomastia / breast tenderness in men (from aromatase inhibition), menstrual-cycle modulation. Community reports of these are essentially absent despite mechanistic plausibility.

FAERS Signal Table (from BioMCP / OpenFDA)

Reading FAERS data: Apigenin appears as SUSPECT in zero FAERS reports. All 8 reports are concomitant noise where apigenin happened to be co-listed with the actual suspect drug. Chamomile as a proxy returns ~26,711 reports — also zero suspect — consistent with the FAERS supplement-noise pattern (concomitant patient-reported supplements inflate apparent risk). No actionable adverse-event signal for apigenin or chamomile as primary agent. Case-report-level safety signals (rare contact allergy, anaphylaxis with Asteraceae sensitivity) exist outside FAERS.

Monitoring Table

Special Populations

Include subsections only where dosing actually changes or specific safety data exists.

Renal Impairment

Hepatic Impairment

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Pharmacogenomic literature on apigenin is essentially absent in humans. All entries above are mechanism-class extrapolations, not compound-specific evidence. Action column reflects reasonable caution, not validated guidance.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-leaning-positive with bifurcation. Two archetypes dominate: (1) sleep/anxiety users at 50 mg PM (Huberman-influenced, mostly positive); (2) CD38/NAD+ longevity seekers at 300–500 mg (Longecity, skeptical, bioavailability-aware). Chamomile tea users report gentle positive effects dominated by ritual/placebo. A loud minority (~10–15% of sleep users) reports paradoxical anxiety or disrupted sleep.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• Life Extension commercial push: Senolytic Activator actively markets apigenin on the CD38/NAD+ angle. Life Extension Magazine content doubles as advertising and dominates Google SERPs, inflating apparent consensus.
• Sinclair / Sirtris conflict of interest: Original CD38/apigenin paper authors were on a provisional patent; one was a Sirtris/GSK consultant. Apigenin rides the coattails of NMN/NR marketing.
• Huberman amplification: The 50 mg dose is a podcast recommendation artifact, not dose-response derived. Chamomile insomnia RCTs are NS on most endpoints.
• Chamomile-placebo confound: Tea ritual, warmth, and hydration carry huge nonspecific effects. Do NOT equate chamomile tea testimonials with apigenin isolate experience.
• Brand variability: Chamomile extracts range 0.5–2% apigenin; "apigenin 98%" isolates are a different exposure. Users frequently conflate the two.
• Bioavailability gap: Longecity users repeatedly flag that oral apigenin plasma levels are low; mouse-to-human extrapolations inflate expectations. Marketing routinely skips this.
• Senolytic-protocol drift: "Two days a month" pulse is extrapolated from dasatinib+quercetin research, not apigenin-specific.
• Affiliate-driven listicles: "Best apigenin supplements 2026" articles are near-100% affiliate-driven (Momentous, NootropicsDepot, Life Extension, Longevity Box recur).
• Under-signaled risk for HRT users / over-signaled for general population: Women's-health communities have not coalesced around apigenin's estrogenic pharmacology; Huberman publicly advises women not to take it, creating unresolved tension with the Examine.com view that 50 mg is ~100–500× below in-vitro ER-activation thresholds.

Folk vs Clinical Reality Check

Where folk and clinical align: chamomile extract for menopausal vasomotor symptoms (anecdote matches RCT), modest calming/anxiolytic effect (aligns with GAD MA). Where they diverge: "50 mg apigenin for sleep" has a strong community narrative but weak direct clinical evidence on the isolate (only chamomile-tea PK and an NS chronic-insomnia pilot); "apigenin boosts NAD+ in humans via CD38" is entirely marketing-and-mechanism driven with zero human NAD+ data. Most likely explanations for divergence: placebo/ritual effect with chamomile, influencer amplification, and insufficient free-aglycone exposure at consumer doses.

Deep Dive: Mechanisms & Research

Mechanisms with Clinical Translation

• GABA-A benzodiazepine-site modulation: Apigenin binds the GABA-A benzodiazepine site (preclinical). Translates to chamomile's measurable anxiolytic effect (PMID 19593179, 27912875, 31006899). The 50 mg isolated-apigenin sleep dose is community-derived and lacks direct RCT evidence.
• CD38 inhibition → NAD+/SIRT1/SIRT3: Escande 2013 (PMID 23172919) is the seminal CD38 inhibitor work. Apigenin-mediated CD38 inhibition has been demonstrated in diabetic kidney (PMID 32507768, Kanazawa), lung fibroblasts (PMID 34049472, Wonkwang), brown adipose/obesity-hypertension (PMID 39218272), cochlear hair cells (PMID 39725836, PLA General Hospital). All preclinical. Zero human data showing oral apigenin raises NAD+.
• Senomorphic (SASP suppression) via PRDX6/HSPA8/ATM-p38MAPK: 2025 landmark (PMID 40265973, Shanghai Univ TCM + Buck Institute + Cedars-Sinai) — apigenin blocks ATM/p38MAPK–HSPA8 interaction and targets PRDX6 iPLA2 activity to prevent ASAP→SASP transition. In aged mice: reduced frailty, improved cognition, enhanced chemotherapy efficacy. Distinguishes apigenin conceptually from BCL-family-targeting senolytics like fisetin or D+Q.
• TRPV4-dependent vasorelaxation: Endothelial TRPV4 activation in BAT → adiponectin → BP lowering (PMID 39218272). Distinct from eNOS.
• p70S6K anabolic signaling (sarcopenia preservation): 50 mg/kg rat apigenin preserved muscle mass in HCD-fed aged rats without preventing obesity (PMID 40652723, 2025). Narrow but real.
• Anti-proliferative (PI3K/Akt/mTOR, Wnt, NF-κB): Consistent across 25+ animal cancer studies (SMD −3.6 tumor volume, PMID 35752426) with funnel-plot-indicated publication bias. No human efficacy trial has completed (OSU breast cancer trial WITHDRAWN).

Pharmacokinetics

• Oral bioavailability ~5% (rodent); human plasma after parsley/chamomile shows mostly glucuronide/sulfate conjugates, Tmax ~7h, long colonic release kinetics.
• Poor water solubility (1–3 μg/mL) — rate-limiting.
• Extensive phase-II conjugation (UGT1A1, UGT1A9, SULT1A1).
• Plasma half-life ~2.5 h (community-cited from rodent PK).
• Resveratrol co-admin raises apigenin plasma ~2.39× in mice.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Regulatory Status (from BioMCP)

• FDA: Not approved as a drug. No Drugs@FDA monograph. Marketed as a dietary supplement under DSHEA. Apigenin isolate is NOT individually listed in the FDA GRAS inventory. Chamomile flower (Matricaria chamomilla) is GRAS as a spice/natural flavoring under 21 CFR 182.10 & 182.20.
• EMA: No drug approval. Chamomile flower (Matricaria recutita flos) is an approved traditional herbal medicinal product via HMPC (traditional use, not well-established efficacy) for mild GI symptoms, minor mouth/throat ulcers, skin inflammation, and nervous tension. Isolated apigenin has no EMA status.
• EU flavoring authorization: Apigenin is authorized as a flavoring substance (FL 16.063) in Reg. (EC) 1334/2008.
• WADA: Not prohibited; not on monitoring list.
• Regulatory context: Not approved as a drug because it is non-patentable, abundant in food, and has never been submitted for approval. This is a commercial-viability status, not a safety verdict. No regulator has issued a warning or suspension related to apigenin.

Ataraxia Verdict (as of 2026-04-18)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature ("it's in chamomile tea, so it's safe and effective"): Dose in tea ≠ dose in 98% isolate. Traditional-use safety record applies to chamomile flower, not isolate at 300–500 mg.
• Hasty generalization (rodent → human longevity): The entire CD38/NAD+/SASP narrative in humans is animal-to-human extrapolation. Cap all such claims at 2/5 / BH 3.
• Appeal to authority (Sinclair / Huberman): Two podcaster/researcher figures dominate English-language discourse. Both have commercial or brand interests. 50 mg sleep dose is a podcast convention, not a dose-response finding.
• Cherry-picking (animal cancer MA): Pandey 2022 MA funnel plot suggests publication bias. Negative animal studies are underrepresented.
• Argument from popularity ("Life Extension sells thousands of bottles"): Marketing volume ≠ evidence strength.
• Equivocation (senolytic vs senomorphic): Marketing freely interchanges these terms. The 2025 PRDX6 paper specifically positions apigenin as senomorphic (SASP-suppressing), NOT senolytic (senescent-cell-killing). Users buying apigenin expecting fisetin-like senescent-cell clearance are paying for a different mechanism.

Evidence Gaps

• No human RCT of isolated apigenin at supplement doses (50–500 mg/d) for any longevity, senotherapeutic, or metabolic endpoint.
• No human dose-response PK on isolate (only single-meal chamomile/parsley PK from 2015).
• No human data on CD38 inhibition or NAD+ elevation.
• No head-to-head vs fisetin, quercetin, luteolin, or SSRIs.
• No pregnancy/lactation safety data.
• No pharmacogenomic stratification.
• No long-term (>12 weeks on isolate) safety data.
• No resolution of the breast-cancer ambiguity (aromatase inhibition could be pro- or anti-proliferative depending on context).
• No independently verified bioavailability for most commercial liposomal/phytosomal products.

Bias Flags (Mode 4: First Principles)

• Mechanism-to-marketing gap: Apigenin has one of the largest mechanism-to-human-evidence gaps in the supplement space. Preclinical is rich; clinical is thin.
• Commercial incentive to conflate chamomile evidence with apigenin isolate evidence: The ONLY positive human evidence is on chamomile extract at doses delivering ~4.8 mg apigenin/day. That evidence is routinely used to justify sale of 50–500 mg isolate capsules.
• Confirmation bias in the longevity sphere: Readers who accept the Sinclair narrative on NMN/NR tend to accept the apigenin CD38 claim without scrutiny. The evidentiary bar is the same — and apigenin is further from it than NMN.
• Survivor bias in community testimonials: People who "didn't feel anything" stop posting; people who had strong subjective effects post enthusiastically.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Life Extension's "Senolytic Activator" actively markets apigenin on the CD38/NAD+ angle; Momentous bundles it into "Huberman sleep stack" packs; affiliate-driven SEO listicles saturate search results. Moderate-to-high manipulation pressure.
• Influencer economics: Huberman (sleep), Sinclair (CD38/NAD+ via Tally Health brand), Rhonda Patrick (secondhand endorsement) dominate English-language discourse. Sinclair's commercial ecosystem (Sirtris → GSK → Tally Health) has vested interest in the NAD+ narrative; apigenin benefits by association.
• Counter-narrative manipulation: Relatively low pharma FUD — apigenin is not a commercial threat to any major drug. The main counter-narrative is women's-health caution (phytoestrogen risk) amplified by Huberman.
• Cui bono summary: Supplement brands win if you take it (at 50–500 mg, several brands charge 3–10× raw material cost). No one meaningfully wins if you don't take it (no competing pharma product). Reader wins if they understand it is most likely a mild GABA-modulator at 50 mg and an expensive way to expose themselves to preclinical-only mechanisms at 300+ mg.
• 10-angle red team highlight: The single most concerning angle is evidence quality vs price — paying Life Extension-level prices for CD38 inhibition based entirely on rodent data, when a $3 chamomile tin delivers equivalent or greater GABA-side effects plus all the human RCT evidence.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 5/10 (compound-intrinsic). Strong preclinical breadth across sleep/anxiety/longevity/hepatoprotective/anti-inflammatory/anti-cancer domains; modest human evidence confined to chamomile extract in GAD and menopause. Mechanistic elegance (GABA-A + CD38 + PRDX6) raises the ceiling, but human-evidence shallowness caps it.
• Opportunity cost: Low financial cost at the chamomile-extract tier ($0.30–0.60/day); moderate at the 98% isolate tier ($0.30–0.60/day for a product with less human evidence than cheaper chamomile); moderate-to-high attention cost in longevity stacks where it competes with better-evidenced compounds (magnesium, fish oil).
• Verdict: CONDITIONAL.
• Conditions: (1) For mild anxiety or menopause vasomotor symptoms, chamomile extract standardized to ≥1.2% apigenin at clinical-trial doses is a reasonable low-risk trial; (2) for sleep onset as part of a stack with magnesium ± L-theanine, 50 mg apigenin isolate is a low-risk trial with the caveat that 10–15% of users report paradoxical effects; (3) for longevity / CD38 / senomorphic claims, the evidence is insufficient to recommend at any price — treat as a preclinical bet, not a validated intervention. Avoid in pregnancy, lactation, ER+ cancer history, and Asteraceae allergy.

Bottom Line

Apigenin is a legitimate bioactive with elegant preclinical pharmacology and modest, single-center human evidence confined to chamomile-extract formats in GAD and menopause. The "longevity supplement" narrative is mechanistically coherent but clinically unproven, and the marketing machinery (Life Extension, Sinclair, Huberman amplification) substantially exceeds the evidence base. At 50 mg pre-bed with magnesium it is a low-cost, low-risk anxiolytic sleep adjunct with placebo-plausible effect size. At 300–500 mg for NAD+/senomorphic purposes it is an expensive rodent-data bet. The biggest honest upgrade to this profile would be any human trial measuring NAD+ after oral apigenin — until that exists, the longevity claim floats.

Practical Notes

Brands & Product Selection

• For anxiety / sleep (human-evidence path): Prefer chamomile extract standardized to ≥1.2% apigenin. Look for Matricaria recutita / chamomilla (German chamomile), not Roman chamomile. Brands with third-party COA (Nature's Way, NOW, Gaia Herbs).
• For longevity (preclinical bet): If pursuing isolate, look for enhanced bioavailability (phytosomal, SNEDDS, liposomal) with independently verified PK; otherwise the 98% powder at 50 mg is likely sub-pharmacologic for the longevity mechanism.
• Red flags: "Clinically proven CD38 inhibition" / "NAD+ booster" claims on labels (human CD38/NAD+ data does not exist); proprietary blends that hide apigenin dose; affiliate-driven "Best of 2026" lists as primary source.
• Quality markers: Third-party COA, identity testing (HPLC), heavy-metals testing, absence of Bacillus / microbial contamination (relevant for chamomile flower products).

Storage & Handling

• Apigenin is moderately stable but sensitive to light and heat. Store in amber bottles at room temperature, away from direct sunlight.
• Chamomile extracts with essential-oil content should be kept cool to avoid terpene degradation.
• Capsule shelf life typically 2–3 years; check manufacturer date.
• Apigenin powder is hygroscopic — keep desiccant in bulk containers.

Palatability & Compliance

• Capsules are the easiest route; no taste issues.
• Chamomile tea is pleasant but delivers sub-pharmacologic isolated-apigenin doses; suitable as a bedtime ritual, not a therapeutic intervention.
• Apigenin powder is bitter and chalky; capsule or tincture form preferred.
• Habit-stack apigenin with magnesium for PM dosing to build a reliable sleep ritual.

Exercise & Circadian Timing

• PM dosing (30 min pre-bed) is the folk default for sleep/anxiolysis.
• AM dosing for CD38/NAD+ aims is community-theorized, without supporting PK rationale.
• Individual biphasic dose-response reports (stimulating at 150–200 mg, sedating at 50 mg) suggest trialing the lowest dose first and adjusting by subjective response.
• No clear exercise-relevant effect; do not expect pre-workout benefit.

Reference Ranges (Expected Biomarker Changes)

Cost

• Chamomile extract (clinical tier): $0.30–$0.60 per day (~$9–$18/month).
• Apigenin 98% isolate: $0.10–$0.30 per 50 mg (~$3–$9/month at 50 mg/d, $18–$54/month at 300 mg/d).
• Phytosomal / liposomal apigenin: $0.50–$1.50 per dose (~$15–$45/month).
• Chamomile tea: ~$0.05 per cup (essentially free as a ritual, sub-pharmacologic as a therapy).
• Cost-effectiveness framing: For the human-evidence-backed uses (GAD, menopause), chamomile extract is more cost-effective than isolate. For the preclinical-only claims, no formulation has demonstrated cost-effectiveness.

What We Don't Know

• Whether oral apigenin at any practical dose measurably raises human NAD+.
• Whether the PRDX6/HSPA8 senomorphic mechanism translates to humans at achievable plasma concentrations.
• Dose-response and ceiling effect on isolate in humans.
• Long-term safety beyond 12 weeks on isolate.
• Clinical magnitude of CYP1A2/CYP3A4 interactions at 300–500 mg/d.
• Pregnancy, lactation, and fertility safety.
• Whether aromatase inhibition is clinically relevant in ER+ cancer history.
• Pharmacogenomic modifiers (COMT, UGT1A1, SULT1A1, CYP1A2) on response.
• Whether phytosomal/liposomal bioavailability claims are independently verified.
• Head-to-head efficacy vs fisetin, quercetin, luteolin, SSRIs, or benzodiazepines.
• Sepsis trial results (NCT05999682 completed, unposted).
• Whether the "50 mg PM for sleep" convention has any dose-response justification or is pure podcast artifact.

References

Systematic Reviews / Meta-analyses

• PMID 31006899 — Hieu et al., Phytother Res 2019 — MA of 12 RCTs on chamomile for GAD/sleep; GAD MD −1.43 to −1.79 HAM-A points.
• PMID 35378276 — Zhang et al., Pharmacol Res 2022 — Bayesian network MA of 29 trials, 12 herbs; chamomile NS vs placebo for anxiolysis; ranked below Silexan, kava.
• PMID 29464801 — Yeung et al., Phytother Res 2018 (MSKCC) — Single-herb SR for onco-psych; chamomile listed among favorable risk-benefit herbs.
• PMID 35752426 — Singh et al., Crit Rev Oncol Hematol 2022 — Animal MA of 25 studies; tumor-volume SMD −3.6 with publication-bias signal.
• PMID 39254067 — Ahmadzadeh et al., Cancer Med 2024 — SR+MA of 39 colorectal adenocarcinoma animal studies.
• PMID 39665306 — Zhang et al., Curr Neuropharmacol 2025 — MA of 13 AD animal studies (N=736 animals).
• PMID 37851868 — Wang et al., J Asthma 2024 — MA of apigenin effects on lung inflammation.
• PMID 35661071 — Rahimi et al., Inflammopharmacology 2022 — MA preclinical lung injury.

Landmark Human RCTs

• PMID 19593179 — Amsterdam et al. 2009 — Chamomile for GAD, N=57, HAM-A P=0.047. First controlled GAD chamomile RCT.
• PMID 27912875 — Mao et al. 2016 — Long-term chamomile for GAD relapse, N=179, HR 0.52 (NS primary); maintained symptom reduction.
• PMID 21939549 — Zick et al. 2011 — Chamomile for chronic primary insomnia, N=34, NS on ISI.
• PMID 31808709 — Amsterdam et al. 2020 — Chamomile oral extract in comorbid GAD + depression.
• PMID 39836709 — Mohsenzadeh-Ledari et al., Menopause 2025 — Triple-blind RCT N=80; chamomile 100 mg × 4/d 1.2% apigenin; total symptom score −10.36 points (p<0.001).
• PMID 32100582 — Rahmati et al. 2021 — Ex vivo PBMC N=5 MS patients; apigenin + apigenin-3-acetate suppressed Th17.
• PMID 41538720 — Nikkhah et al., Anticancer Drugs 2026 — Chamomile oral solution vs paclitaxel-induced neurotoxicity.

Mechanism / Foundational

• PMID 23172919 — Escande et al. 2013 — Seminal CD38 inhibitor paper; apigenin and related flavonoids.
• PMID 34049472 — Li et al., Am J Chin Med 2021 — SIRT1–NAD+–CD38 axis in lung fibroblast senescence.
• PMID 32507768 — Ogura et al., Aging 2020 — CD38/Sirt3 in diabetic kidney.
• PMID 40265973 — Zhang et al., Adv Sci 2025 — PRDX6/HSPA8 senomorphic mechanism (landmark).
• PMID 38476603 — Kramer & Johnson, Front Nutr 2024 — Sleep + aging + CD38/NAD+ integration review.
• PMID 39725836 — Liu et al., Mol Neurobiol 2025 — CD38/NF-κB coordination in noise-induced hearing loss.
• PMID 39218272 — Mou et al., BBA Mol Basis Dis 2024 — TRPV4 vasorelaxation + CD38-adiponectin axis in obesity-HTN.
• PMID 40652723 — de Castro et al., Biomed Pharmacother 2025 — p70S6K preservation of muscle in aged rats (negative on obesity).
• PMID 36646447 — Chiu et al., Biomol Ther Seoul 2023 — Aβ/TRKB signaling.
• PMID 40111567 — Bhratee et al., Metab Brain Dis 2025 — GSK-3β in cognitive impairment.
• PMID 36746671 — Pandey et al. 2023 — Oncogenic pathway review.
• PMID 40827276 — Chen et al., Clin Interv Aging 2025 — Phytoestrogen / bone review.
• PMID 41620007 — Juan et al., Eur J Pharmacol 2026 — Natural senotherapeutics in respiratory aging.
• PMID 40005954 — Della Vedova et al., Pharmaceuticals 2025 — Polyphenols modulating senescence.
• PMID 36100824 — Mbara et al. 2022 — Flavonoid senotherapeutic review.

Hepatoprotective / Metabolic

• PMID 39749193 — Wang et al., Front Pharmacol 2024 — Comprehensive hepatoprotective review.
• PMID 41865215 — Huang et al., Sci Rep 2026 — Apigenin + aerobic exercise in NAFLD mice.
• PMID 38629096 — Javadi & Sobhani 2024 — Metabolic-syndrome SR.
• PMID 35046924 — Qiao et al., Front Microbiol 2021 — Gut microbiome modulation of metabolic syndrome.
• PMID 38906017 — Shahab et al., Biomed Pharmacother 2024 — Insulin secretion via PKA-MEK.

Pharmacokinetics / Formulation

• PMID 16407641 — Parsley-to-human PK.
• PMID 27766890 — Oral apigenin PK review.
• PMID 34084146 — Oral apigenin GI cancer feasibility.
• PMID 39738511 — Sato et al. 2024 — SNEDDS bioavailability enhancement.
• PMID 39859284 — Rosiak et al. 2025 — Solid dispersions.
• PMID 39259258 — Kumar et al. 2024 — Nano-based delivery review.
• PMID 40600357 — Ji et al. 2025 — Barley protein-apigenin covalent complexes.
• PMID 34740050 — Li et al., Food Chem 2022 — Apigenin-oxymatrine co-amorphous.
• PMID 38735632 — Bonilla-Vidal et al. 2024 — Lipid nanocarriers ocular delivery.

Gut / Microbiome / Radiation

• PMID 36590200 — Fu et al., Front Nutr 2022 — Gut microbiota remodeling in UC.
• PMID 38542210 — Magadán-Corpas et al., IJMS 2024 — IP apigenin in rat UC.
• PMID 38373016 — Rithidech et al., Radiat Res 2024 — Radiation-induced gut dysbiosis prevention.

Guidelines / Regulatory-adjacent

• PMID 33467951 — 2021 Mucositis Nursing CPG — chamomile oil listed as clinical-experience-effective.
• PMID 37397764 — 2023 CAM-for-insomnia SR of 17 CPGs — chamomile explicitly NOT recommended.
• PMID 38604221 — 2024 Phytotherapy in Gastroenterology review — chamomile in GI guidelines.

Safety

• PMID 26853158 — Apigenin neither mutagenic nor genotoxic.

Additional Mechanistic / Emerging

• PMID 40426656 — Kruszka et al., Brain Sci 2025 — Flavonoid neuroinflammation in AD.
• PMID 40667502 — Asiri et al., Front Pharmacol 2025 — Apigenin + curcumin + EGCG in cervical cancer.
• PMID 39318018 — Singh et al. 2025 — Combined flavonoid anticancer review.
• PMID 40635287 — Li et al. 2025 — Anticancer and toxicity profile of apigenin and luteolin.
• PMID 41268159 — Balkrishna et al. 2025 — Apigenin + ellagic acid for PCOS comorbidities (review).